| 產(chǎn)品編號(hào) | bs-17478R-RBITC |
| 英文名稱1 | Rabbit Anti-Melanoma gp100/RBITC Conjugated antibody |
| 中文名稱 | 羅丹明（RBITC）標(biāo)記的黑色素瘤相關(guān)抗原gp100抗體 |
| 別 名 | 95 kDa melanocyte specific secreted glycoprotein; 95 kDa melanocyte-specific secreted glycoprotein; D12S53E; gp100; M-beta; ME20; ME20 M/ME20 S; ME20-M; ME20-S; ME20M; ME20M/ME20S; ME20S; Melanocyte lineage specific antigen GP100; Melanocyte protein mel 17; Melanocyte protein Pmel 17; Melanocyte protein Pmel 17 precursor; Melanocytes lineage-specific antigen GP100; Melanoma associated ME20 antigen; Melanoma gp100; Melanoma-associated ME20 antigen; Melanosomal matrix protein 17; Melanosomal matrix protein17; P1; p100; p26; PMEL 17; PMEL; PMEL_HUMAN; PMEL17; Premelanosome protein; Secreted melanoma-associated ME20 antigen; SI; SIL; SILV; Silver (mouse homolog) like; Silver homolog; Silver locus protein homolog; Silver, mouse, homolog of. |
| 規(guī)格價(jià)格 | 100ul/2980元 購(gòu)買 大包裝/詢價(jià) |
| 說(shuō) 明 書 | 100ul |
| 研究領(lǐng)域 | 腫瘤 細(xì)胞生物 細(xì)胞類型標(biāo)志物 腫瘤細(xì)胞生物標(biāo)志物 |
| 抗體來(lái)源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | (predicted: Human, Horse, ) |
| 產(chǎn)品應(yīng)用 | ICC=1:50-200 IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 68kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human Melanoma gp100 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲(chǔ) 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: This gene encodes a melanocyte-specific type I transmembrane glycoprotein. The encoded protein is enriched in melanosomes, which are the melanin-producing organelles in melanocytes, and plays an essential role in the structural organization of premelanosomes. This protein is involved in generating internal matrix fibers that define the transition from Stage I to Stage II melanosomes. This protein undergoes a complex pattern of prosttranslational processing and modification that is essential to the proper functioning of the protein. A secreted form of this protein that is released by proteolytic ectodomain shedding may be used as a melanoma-specific serum marker. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Jan 2011] Function: Plays a central role in the biogenesis of melanosomes. Involved in the maturation of melanosomes from stage I to II. The transition from stage I melanosomes to stage II melanosomes involves an elongation of the vesicle, and the appearance within of distinct fibrillar structures. Release of the soluble form, ME20-S, could protect tumor cells from antibody mediated immunity. Subcellular Location: Secreted and Endoplasmic reticulum membrane. Golgi apparatus. Melanosome. Endosome > multivesicular body. Identified by mass spectrometry in melanosome fractions from stage I to stage IV. Localizes predominantly to intralumenal vesicles (ILVs) within multivesicular bodies. Associates with ILVs found within the lumen of premelanosomes and melanosomes and particularly in compartments that serve as precursors to the striated stage II premelanosomes.Target information above from: UniProt accession P40967 The UniProt Consortium The Universal Protein Resource (UniProt) in 2010 Nucleic Acids Res. 38:D142-D148 (2010) . Tissue Specificity: Preferentially expressed in melanomas. Some expression was found in dysplastic nevi. Not found in normal tissues nor in carcinomas. Normally expressed at low levels in quiescent adult melanocytes but overexpressed by proliferating neonatal melanocytes and during tumor growth. Post-translational modifications: A small amount of P1/P100 (major form) undergoes glycosylation to yield P2/P120 (minor form). P2 is cleaved by a furin-like proprotein convertase (PC) in a pH-dependent manner in a post-Golgi, prelysosomal compartment into two disulfide-linked subunits: a large lumenal subunit, M-alpha/ME20-S, and an integral membrane subunit, M-beta. Despite cleavage, only a small fraction of M-alpha is secreted, whereas most M-alpha and M-beta remain associated with each other intracellularly. M-alpha is further processed to M-alpha N and M-alpha C. M-alpha C further undergoes processing to yield M-alpha C1 and M-alpha C3 (M-alpha C2 in the case of PMEL17-is or PMEL17-ls). Formation of intralumenal fibrils in the melanosomes requires the formation of M-alpha that becomes incorporated into the fibrils. Stage II melanosomes harbor only Golgi-modified Pmel17 fragments that are derived from M-alpha and that bear sialylated O-linked oligosaccharides. N-glycosylated. O-glycosylated; contains sialic acid. Similarity: Belongs to the PMEL/NMB family. Contains 1 PKD domain. Database links: Entrez Gene: 6490 Human Entrez Gene: 20431 Mouse Omim: 155550 Human SwissProt: P40967 Human SwissProt: Q60696 Mouse Unigene: 95972 Human Unigene: 16756 Mouse Unigene: 162910 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
